Figure 6 Assessment of colonic transit time with radiopaque markers

Slides:



Advertisements
Similar presentations
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Advertisements

Figure 3 Low-grade inflammation in FGID
Figure 2 Enteroids can model transport physiology
Figure 1 Imaging of a depressed intramucosal carcinoma
Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Injection of mesenchymal stem cells in perianal fistulas
Figure 2 The three most commonly performed bariatric surgical procedures Figure 2 | The three most commonly performed bariatric surgical procedures. a.
Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process
Figure 3 Algorithm from working group describing
Figure 2 Effect of PPIs on gastric physiology
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.
Figure 6 Combination therapy for HCC
Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.
Figure 1 Definition and concept of ACLF
Figure 2 Switching of biologic agents and biosimilars
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 High-resolution manometry of achalasia subtypes
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Example wireless motility recording
Investigation of Colonic and Whole-Gut Transit With Wireless Motility Capsule and Radiopaque Markers in Constipation  Satish S.C. Rao, Braden Kuo, Richard.
Figure 2 Key metrics of pressure topography (Clouse)
to the liver and promote patient-derived xenograft tumour growth
Figure 7 Example colonic high-resolution manometry
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Pseudorelaxation as a consequence of
Figure 1 Environmental factors contributing to IBD pathogenesis
Figure 4 Example plots of high-resolution gastroduodenal manometry
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 4 Examples of reflux episodes on pH and pH-impedance monitoring
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.
Figure 2 13C-octanoic acid gastric emptying breath test
Figure 4 Functional luminal imaging probe
in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)
Figure 5 Representative barium defecography images
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Metrics from oesophageal high-resolution
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 5 High-resolution manometry studies performed
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 5 Systems biological model of IBS
Figure 4 Local species pools that contribute to the
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Distribution of markers of active HBV infection
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Lifelong influences on the gut microbiome from
Figure 2 Classifications and appearance of CCAs
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 8 Assessment of colonic tone using a barostat device
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Clinical Case: Chronic Constipation
Presentation transcript:

Figure 6 Assessment of colonic transit time with radiopaque markers Figure 6| Assessment of colonic transit time with radiopaque markers. A radiopaque marker test of a patient who ingested 10 markers every morning for 6 days is shown. The plain abdominal radiograph was taken on day 7 and shows that all 60 markers are retained; accordingly, colonic transit time is ≥144 h ((number of retained capsules × 24 h)/(number of capsules ingested per day)). Normal values include colonic transit times ≤70 h in a mixed population, ≤50 h in men and ≤70–106 h in women. Note that in this case, the markers are evenly distributed throughout the colon, which is regarded as typical of, but is not completely specific for, slow-transit constipation. Keller, J. et al. (2018) Advances in the diagnosis and classification of gastric and intestinal motility disorders Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2018.7